CTOR · Citius Oncology, Inc.
$0.85
+0.00 (+0.00%)
At close · Oct 7
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“We will need to raise additional capital to support our operations beyond November 2026, which raises substantial doubt about our ability to continue as a going concern within one year after the date that the accompanying financial statements are issued.”View the 10-Q filed Aug 14, 2026
Market Cap
$94.92M
Shares
92.98M
Volume · Oct 7
14.91K
Avg daily vol (3M)
98.03K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.85
Open$0.86
Day$0.81–0.92
52W close$0.49–1.88
Avg vol 30d97K
Short int510K · 0.5% float · 6.9d
Short vol38%
DataDec 2022–Oct 2026
Filing10-Q · Aug 14
Up next
filed Aug 14, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$46.06M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$16.56M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+50.8%
Year over year · more shares
Price change (1Y)
-53.8%
Trailing year
Short interest
0.5%
Latest settlement · 6.9 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Neutral
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 15 · calm
Equity put/call 0.57
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−3%
below
Price vs 50-day avg
+1%
above
RSI (14)
42
neutral
MACD trend
Negative
52-week position
26%
mid-range
Volume (OBV)
Bullish div.
accumulating
Momentum
relative strength
1-month return
−9%
trailing
6-month return
+2%
trailing
YTD return
−15%
this year
Relative strength
−9%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Accumulating
+36% holders QoQ · +7 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.55% of float · ▲ +8.7% MoM · 6.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
19 holders — mid 3-yr range
Squeeze score
58
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
92%
annualized · 1-yr
Max drawdown
−74%
past year
ATR
11.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−3%
Neutral
Price vs 50-day avg
+1%
Bullish
RSI (14)
42
Neutral
MACD trend
Negative
Bearish
52-week position
26%
Neutral
Volume (OBV)
Bullish div.
Bullish
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Accumulating
+36% holders QoQ · +7 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.55% of float · ▲ +8.7% MoM · 6.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
19 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $0
Now $1 · 26%
Range high $2
vs 200-day avg -3%
vs 50-day avg +1%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Increase in number of new ordering institutions (quarter ended June 30, 2026 vs. quarter ended M | 80% | the quarter ended June 30, 2026 compared to the quarter ended Ma filing | — |
| Increase in vials ordered by institutions from wholesalers (quarter ended June 30, 2026 vs. quar | 31% | the quarter ended June 30, 2026, compared to the quarter ended M filing | — |
| institutional vial orders | 926 | the quarter ended June 30, 2026 | — |
| institutions that have prescribed and ordered LYMPHIR | 44 | the quarter ended June 30, 2026 | — |
| Vials ordered by institutions from wholesalers (quarter ended March 31, 2026) | 708 | the quarter ended March 31, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CTOR
this stock
Citius Oncology, Inc.
|
$94.92M | -15.0% | — | — | 0.5% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$60.23B | +16.1% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$46.00B | -6.7% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$45.67B | +25.4% | +4.3% | 64.3 | 2.7% |
|
HLN
Haleon plc
|
$40.72B | -12.3% | — | — | 0.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CTOR | -19.1% | -8.5% | +2.4% | -15.8% | -15.0% |
| SPY | +2.0% | +1.7% | +11.3% | +2.2% | +14.3% |
| vs SPY | -21.0% | -10.2% | -8.9% | -18.0% | -29.3% |